NLS Pharmaceutics Expands CNS Pipeline With AEX-6xx Series Developed by Aexon Labs

Seeking Alpha / 1 Views

DOXA Platform Expansion Strengthens Cognitive, Arousal, and Neuroprotective Programs Supported by Solid Cash Position and Strategic Funding Outlook ZURICH, Oct. 30, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd. (Nasdaq: NLSP)(Nasdaq: NLSPW) ("NLS"), a Swiss clinical-stage biopharmaceutical...

Comments